English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#gprc5d search results

onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Sep 15, 2023

1-2> Matching modality to mechanism. The title above is something I've often commented on on Twitter, so it was nice to see. For example, #BMS has seen #GPRC5D as a more appropriate modality for cell therapy than bispecific antibodies, though I don't know the specific reasons.

onco_park's tweet image. 1-2> Matching modality to mechanism. The title above is something I've often commented on on Twitter, so it was nice to see. For example, #BMS has seen #GPRC5D as a more appropriate modality for cell therapy than bispecific antibodies, though I don't know the specific reasons.
0
0
0
2
1K
BertrandBio's profile picture. Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design) & 10y following bios. Preplanned pause.
Bertrand Delsuc
 @BertrandBio
Dec 12, 2022

Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…

BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
0
0
2
1
0
frankvinluan's profile picture. Business journalist based in #RTP, covering pharma and biotech (almost) everywhere. 71% free throw shooter. Genesis: Album 9, track 11.
Frank Vinluan
 @frankvinluan
Dec 12, 2022

#Talquetamab is a bispecific antibody. The cancer-targeting part binds to #GPRC5D, a protein found on some normal cells but abundant on #myeloma cells, making it a good drug target. The $JNJ drug could become the first one approved for targeting GPRC5D.

1
0
0
0
0
onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Nov 3, 2023

BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…

onco_park's tweet image. BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…
onco_park's tweet image. BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…
0
0
0
0
185
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 31, 2022

⚡️ La thérapie #CAR_Tcell 🩸 ciblée par l'antigène #GPRC5D induit une forte réponse dans le #MyélomeMultiple 👉#MCARH109, ​​une thérapie #CAR_T 🩸 ciblant l'antigène GPRC5D, a généré des rémissions chez 70,6 % des patients atteints de #Myélome multiple R/R www2.onclive.com/view/gprc5d-an…

jyves94's tweet image. ⚡️ La thérapie #CAR_Tcell 🩸 ciblée par l'antigène #GPRC5D induit une forte réponse dans le #MyélomeMultiple 👉#MCARH109, ​​une thérapie #CAR_T 🩸 ciblant l'antigène GPRC5D, a généré des rémissions chez 70,6 % des patients atteints de #Myélome multiple R/R www2.onclive.com/view/gprc5d-an…
0
0
0
0
0
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Jan 31, 2023

⚡️#TheLancet 👉Cellules #CAR_T #GPRC5D (#OriCAR_017) chez des patients atteints d’un #MyélomeMultiple #POLARIS en R/R, 1er essai de #Phase1 chez l’homme 👉La thérapie par #CAR_T ciblant #BCMA a montré une activité dans le traitement du #MyélomeMultiple R/R thelancet.com/journals/lanha…

jyves94's tweet image. ⚡️#TheLancet 👉Cellules #CAR_T #GPRC5D (#OriCAR_017) chez des patients atteints d’un #MyélomeMultiple #POLARIS en R/R, 1er essai de #Phase1 chez l’homme 👉La thérapie par #CAR_T ciblant #BCMA a montré une activité dans le traitement du #MyélomeMultiple R/R thelancet.com/journals/lanha…
0
0
0
0
66
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Dec 11, 2022

Les chercheurs espéraient que la protéine #GPRC5D pourrait offrir une façon d'amener le système immunitaire à traquer & à détruire les cellules de #MyélomeMultiple 🩸 👉Les résultats d'une étude de Phase 2 sur un #AnticorpsBispécifique ciblant cette protéine viennent le confirmer

jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Dec 11, 2022

🩸#NEWORLEANS 🇺🇸- « Nous avons une nouvelle cible » : un #AnticorpsBispécifique pour le #MyélomeMultiple 🩸 réussit un essai à mi-parcours #ASH2022 #GPRC5D statnews.com/2022/12/10/bis…

jyves94's tweet image. 🩸#NEWORLEANS 🇺🇸- « Nous avons une nouvelle cible » : un #AnticorpsBispécifique pour le #MyélomeMultiple 🩸 réussit un essai à mi-parcours #ASH2022 #GPRC5D statnews.com/2022/12/10/bis…
0
0
0
0
0
1
0
0
0
0
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Jul 2, 2022

🩸 Le #Talquetamab est un anticorps bispécifique expérimental, prêt à l'emploi, qui redirige les lymphocytes T ciblant à la fois le #GPRC5D, une nouvelle cible médicamenteuse, sur les cellules de #Myélome_Multiple et le #CD3 sur les #LymphocytesT.

jyves94's tweet image. 🩸 Le #Talquetamab est un anticorps bispécifique expérimental, prêt à l'emploi, qui redirige les lymphocytes T ciblant à la fois le #GPRC5D, une nouvelle cible médicamenteuse, sur les cellules de #Myélome_Multiple et le #CD3 sur les #LymphocytesT.
0
0
0
0
0
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Aug 26, 2023

Cela conduit à l'activation des #Cellules_T et à la lyse ultérieure des cellules exprimant #GPRC5D par la perforine sécrétée et diverses #Granzymes stockées dans les vésicules sécrétoires des cellules T cytotoxiques

1
0
0
0
57
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 10, 2022

🩸 L'essai de la thérapie #CAR_TCell ciblant le #GPRC5D montre son efficacité dans le #MyélomeMultiple résistant R/R, & révèle des #Rémissions chez 70,6 % des patients inscrits. 👉 Le #CAR_T a produit des résultats impressionnants ! #CARTCR #ImmunoTherapy buff.ly/3MdehGe

jyves94's tweet image. 🩸 L'essai de la thérapie #CAR_TCell ciblant le #GPRC5D montre son efficacité dans le #MyélomeMultiple résistant R/R, & révèle des #Rémissions chez 70,6 % des patients inscrits. 👉 Le #CAR_T a produit des résultats impressionnants ! #CARTCR #ImmunoTherapy buff.ly/3MdehGe
0
0
0
0
0
cancer_navi's profile picture. がんとの闘いは“情報戦”。どこに有益な情報があるのか、氾濫する情報の中でどれが大切なのか―。情報を選り分ける力がますます大切になっています。がんナビは、がん患者さんとそのご家族のために、がんの治療や患者さんの日々の生活をナビゲート（道案内）します。がんナビは、1972年創刊の総合医療情報誌『日経メディカル』運営します。
がんナビ通信
 @cancer_navi
Aug 24, 2023

#GPRC5D と #CD3 に対する二重特異性抗体 #talquetamab が少なくとも3ラインの治療歴を有する成人の再発・難治性 #多発性骨髄腫 を対象に欧州で条件付き承認を獲得しました。 medical.nikkeibp.co.jp/leaf/all/cance…

0
0
4
0
615
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Sep 15, 2023

#BMS 🇺🇸 a souligné son intention de lancer l’essai d’enregistrement de BMS-986393 (CC-95266; #GPRC5D #CAR_T ✂️) au S1 2024 ainsi que son intention de soumettre une IND pour l’enquête sur BMS-986353 (CC-97540 #CD19 NEX-T #CAR_T ✂️) dans la #ScléroseEnPlaques (#MS) en 09 2023

1
0
0
0
75
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Feb 5, 2023

🩸 L'essai de #Phase1 #POLARIS ciblées par #GPRC5D a montré un taux de réponse global de 100 % pour #OriCAR_017, une nouvelle thérapie #CAR_Tcell avec une nouvelle cible dans le #MyélomeMultiple R/R. targetedonc.com/view/gprc5d-ta…

jyves94's tweet image. 🩸 L'essai de #Phase1 #POLARIS ciblées par #GPRC5D a montré un taux de réponse global de 100 % pour #OriCAR_017, une nouvelle thérapie #CAR_Tcell avec une nouvelle cible dans le #MyélomeMultiple R/R. targetedonc.com/view/gprc5d-ta…
0
0
0
0
276
1stOncology's profile picture. Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.
1stOncology
 @1stOncology
Sep 29, 2022

#EurekaTherapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating #GPRC5D as an Active Target for the Treatment of #MultipleMyeloma 1stoncology.com/blog/eureka-th…

0
0
0
0
0
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
Mar 27, 2023

Although the #GPRC5D gene is typically expressed in hair follicles, CD138-positive multiple myeloma cells have also been found to express GPRC5D. Learn more about the GPRC5D gene in its #BiologicalPathwayReview! hmpgloballearningnetwork.com/site/onc/biolo…

OncLearnNetwork's tweet image. Although the #GPRC5D gene is typically expressed in hair follicles, CD138-positive multiple myeloma cells have also been found to express GPRC5D. Learn more about the GPRC5D gene in its #BiologicalPathwayReview! hmpgloballearningnetwork.com/site/onc/biolo…
0
0
0
0
98
_timos_'s profile picture. BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Dr Timos Papagatsias
 @_timos_
Oct 13

LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!

_timos_'s tweet image. LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!
0
0
0
0
17
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
May 13

CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0

OncLearnNetwork's tweet image. CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0
0
0
0
0
52
AlpVHHs's profile picture. AlpVHHs® specializes in developing and producing customized, high-performance alpaca nanobodies.
AlpVHHs
 @AlpVHHs
Apr 17

🔬AlpVHHs Pipeline Highlight: BS016 targeting GPRC5D for Multiple Myeloma (MM)! Advancing our VHH program against this key GPCR target in MM. Full details：👉alpvhhs.com/pipeline/ #Nanobody #VHH #GPRC5D #MultipleMyeloma #Biotech #AACR26

AlpVHHs's tweet image. 🔬AlpVHHs Pipeline Highlight: BS016 targeting GPRC5D for Multiple Myeloma (MM)! Advancing our VHH program against this key GPCR target in MM. Full details：👉alpvhhs.com/pipeline/ #Nanobody #VHH #GPRC5D #MultipleMyeloma #Biotech #AACR26
AlpVHHs's tweet image. 🔬AlpVHHs Pipeline Highlight: BS016 targeting GPRC5D for Multiple Myeloma (MM)! Advancing our VHH program against this key GPCR target in MM. Full details：👉alpvhhs.com/pipeline/ #Nanobody #VHH #GPRC5D #MultipleMyeloma #Biotech #AACR26
0
0
0
0
84
MAWildgust's profile picture. VP of Oncology Global Medical Affairs at Johnson & Johnson, focused on bringing new treatment options for pts with cancer. Tweets/views shared are my own
Mark Wildgust (he/him)
 @MAWildgust
Apr 9

Enjoyed presenting @DAVAOnc #HemeDAVA meeting on #GPRC5D taste changes & #TALISMAN study & learnings. Great panel led by @AlGarfall & honored to be part of it with @DoctorAKrishnan @GKaurMD & Dr Raza. We've made progress but we also need to help patients live well too #MyCompany

MAWildgust's tweet image. Enjoyed presenting @DAVAOnc #HemeDAVA meeting on #GPRC5D taste changes & #TALISMAN study & learnings. Great panel led by @AlGarfall & honored to be part of it with @DoctorAKrishnan @GKaurMD & Dr Raza. We've made progress but we also need to help patients live well too #MyCompany
MAWildgust's tweet image. Enjoyed presenting @DAVAOnc #HemeDAVA meeting on #GPRC5D taste changes & #TALISMAN study & learnings. Great panel led by @AlGarfall & honored to be part of it with @DoctorAKrishnan @GKaurMD & Dr Raza. We've made progress but we also need to help patients live well too #MyCompany
MAWildgust's tweet image. Enjoyed presenting @DAVAOnc #HemeDAVA meeting on #GPRC5D taste changes & #TALISMAN study & learnings. Great panel led by @AlGarfall & honored to be part of it with @DoctorAKrishnan @GKaurMD & Dr Raza. We've made progress but we also need to help patients live well too #MyCompany
1
1
10
0
253
advisains's profile picture. Distributor Bioteknologi: Solusi lengkap teknologi DNA → Cell → Protein Untuk riset, klinikal & industri life science 📩 Konsultasi Gratis
ADVISAINS.ID
 @advisains
Mar 19

🔥 New: GPRC5D antibody [EPR2837641] (ab315808). ✅Recombinant Antibody ✅IHC on TMAs & myeloma ✅Leica BOND® RXvalidated ✅reliable supply See data: go to Abcam and search “ab315808.” #GPRC5D #IHC #RecombinantAntibody

advisains's tweet image. 🔥 New: GPRC5D antibody [EPR2837641] (ab315808). ✅Recombinant Antibody ✅IHC on TMAs & myeloma ✅Leica BOND® RXvalidated ✅reliable supply See data: go to Abcam and search “ab315808.” #GPRC5D #IHC #RecombinantAntibody
advisains's tweet image. 🔥 New: GPRC5D antibody [EPR2837641] (ab315808). ✅Recombinant Antibody ✅IHC on TMAs & myeloma ✅Leica BOND® RXvalidated ✅reliable supply See data: go to Abcam and search “ab315808.” #GPRC5D #IHC #RecombinantAntibody
advisains's tweet image. 🔥 New: GPRC5D antibody [EPR2837641] (ab315808). ✅Recombinant Antibody ✅IHC on TMAs & myeloma ✅Leica BOND® RXvalidated ✅reliable supply See data: go to Abcam and search “ab315808.” #GPRC5D #IHC #RecombinantAntibody
0
0
0
0
27
_timos_'s profile picture. BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Dr Timos Papagatsias
 @_timos_
Oct 13

LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!

_timos_'s tweet image. LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!
0
0
0
0
17
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 8

Thérapie par #CAR_T 🧬 ciblée par #GPRC5D (#CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme. Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20). thelancet.com/journals/lanha…

jyves94's tweet image. Thérapie par #CAR_T 🧬 ciblée par #GPRC5D (#CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme. Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20). thelancet.com/journals/lanha…
0
1
1
0
46
Oncologynewspro's profile picture. Focusing on the cutting-edge information of tumor diagnosis and treatment.
Oncology News
 @Oncologynewspro
Sep 21

Fang Baijun's team from Henan Cancer Hospital published a review in the British Journal of Haematology, focusing on the GPRC5D target and explaining its key role in tumor biology. They also reviewed the cutting-edge progress such as CAR-T/NK cell therapy and ADC drugs.#GPRC5D

Oncologynewspro's tweet image. Fang Baijun's team from Henan Cancer Hospital published a review in the British Journal of Haematology, focusing on the GPRC5D target and explaining its key role in tumor biology. They also reviewed the cutting-edge progress such as CAR-T/NK cell therapy and ADC drugs.#GPRC5D
Oncologynewspro's tweet image. Fang Baijun's team from Henan Cancer Hospital published a review in the British Journal of Haematology, focusing on the GPRC5D target and explaining its key role in tumor biology. They also reviewed the cutting-edge progress such as CAR-T/NK cell therapy and ADC drugs.#GPRC5D
Oncologynewspro's tweet image. Fang Baijun's team from Henan Cancer Hospital published a review in the British Journal of Haematology, focusing on the GPRC5D target and explaining its key role in tumor biology. They also reviewed the cutting-edge progress such as CAR-T/NK cell therapy and ADC drugs.#GPRC5D
0
0
0
0
56
stellanewslife's profile picture. 最新ニュースをお届けする https://t.co/TrisgKCaVP（https://t.co/TrisgKCaVP）。AIを活用し、主に科学技術の情報を効率的に発信中。誤りがあればご指摘ください。皆さまと共に正確な情報を共有します。お気軽にフォローしてください。
STELLANEWS.LIFE
@stellanewslife
Aug 1

Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma sanofi.com/en/media-room/… #Sanofi #SAR446523 #GPRC5D #OrphanDrug #MultipleMyeloma #MonoclonalAntibody #Oncology #Hematology #RareDiseases

0
0
0
0
77
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
Jun 26

Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as #GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory #MM. Learn more: hubs.ly/Q03tTTZk0

OncLearnNetwork's tweet image. Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as #GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory #MM. Learn more: hubs.ly/Q03tTTZk0
0
0
0
0
55
BhaarathP10039's profile picture. Analyst @Larvol
Bhaarath PG
@BhaarathP10039
Jun 14

GPRC5D-Targeting Studies in Multiple Myeloma @EHA_Hematology 2025. #EHA2025 #EHA25 #GPRC5D #Immunotherapy #Talvey #SAR446523 #JNJ5322 #Arlocabtagene #Hematology #Cancer #Oncology #Myeloma #mmsm #TRIMM3 #RedirecTT1 #MonumenTAL1 #QUINTESSENTIAL #MedTwitter #CancerResearch #LARVOL

Larvol's profile picture. At the intersection of #AI & #Oncology data. We provide clinical intelligence, trial insights & competitive analysis for #Pharmaceutical & #BioTech.
LARVOL
@Larvol
Jun 14

Comparative Landscape of GPRC5D-Targeting and Next-Gen Therapies in Relapsed/Refractory Multiple Myeloma at @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #Myeloma #CancerResearch #Oncology #CancerData

Larvol's tweet image. Comparative Landscape of GPRC5D-Targeting and Next-Gen Therapies in Relapsed/Refractory Multiple Myeloma at @EHA_Hematology 2025. Follow us for the latest #EHA2025 updates: t.ly/6uoHY #LARVOL #Hematology #Myeloma #CancerResearch #Oncology #CancerData
0
9
19
7
2K
0
1
4
0
249
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
May 13

CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0

OncLearnNetwork's tweet image. CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0
0
0
0
0
52
MSKLibrary's profile picture. Medical Library of @MSKCancerCenter - Posts reflect library staff opinions, not necessarily MSK's BlueSky: @msklibrary.bsky.social
MSK Library
@MSKLibrary
Mar 12, 2025

Featured today by @MSKLibrary: Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis #CAR_TCellTherapy #MultipleMyeloma #GPRC5D #CancerResearch

MSKLibrary's tweet image. Featured today by @MSKLibrary: Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis #CAR_TCellTherapy #MultipleMyeloma #GPRC5D #CancerResearch
0
3
6
0
612
dr_ugarte's profile picture. Internal Medicine 🇬🇹 and currently third year fellow of Hematology and Transplant in Hospital Universitario Dr. José E. González in Monterrey 🇲🇽
Paulo Ugarte
 @dr_ugarte
Mar 2, 2025

Although it was also cool the analogy of #GPRC5D bispecific followed by CAR-T against #BCMA as el chicharito in the Mexico vs Croatia game ⚽

RahulBanerjeeMD's profile picture. Asst Professor @UWMedicine @fredhutch. Goals: improve pt experience in myeloma #MMsm: ⬇️ dex, ⬆️ time at home, 📱-based wellness. COI: https://t.co/3Uuojuio6R
Rahul Banerjee, MD, FACP
@RahulBanerjeeMD
Mar 1, 2025

#BeyondBlood in CDMX: Según @Rfonsi1, tratar el mieloma en los mayores es como ir a pescar 🎣 Such a cool analogy! Need to maintain line tension just right to catch #MMsm fish in ASCT-ineligible pts - if too much dex or too little dara, you may not achieve the best outcomes!

RahulBanerjeeMD's tweet image. #BeyondBlood in CDMX: Según @Rfonsi1, tratar el mieloma en los mayores es como ir a pescar 🎣 Such a cool analogy! Need to maintain line tension just right to catch #MMsm fish in ASCT-ineligible pts - if too much dex or too little dara, you may not achieve the best outcomes!
0
3
17
1
2K
1
1
2
1
808
Genomeditech's profile picture. Credible Cells For Incredible Discoveries！ Email: mkt.genomeditech@gmail.com LinkedIn：https://t.co/bdOcfBnLjx
Genomeditech
 @Genomeditech
Jan 14, 2025

#GPRC5D AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager. The candidate, SIM0500, is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3.Learn about our catalog: en.genomeditech.com

Genomeditech's tweet image. #GPRC5D AbbVie pens $1B deal for Simcere’s phase 1 T-cell engager. The candidate, SIM0500, is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3.Learn about our catalog: en.genomeditech.com
0
0
0
0
70
No results for "#gprc5d"
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 31, 2022

⚡️ La thérapie #CAR_Tcell 🩸 ciblée par l'antigène #GPRC5D induit une forte réponse dans le #MyélomeMultiple 👉#MCARH109, ​​une thérapie #CAR_T 🩸 ciblant l'antigène GPRC5D, a généré des rémissions chez 70,6 % des patients atteints de #Myélome multiple R/R www2.onclive.com/view/gprc5d-an…

jyves94's tweet image. ⚡️ La thérapie #CAR_Tcell 🩸 ciblée par l'antigène #GPRC5D induit une forte réponse dans le #MyélomeMultiple 👉#MCARH109, ​​une thérapie #CAR_T 🩸 ciblant l'antigène GPRC5D, a généré des rémissions chez 70,6 % des patients atteints de #Myélome multiple R/R www2.onclive.com/view/gprc5d-an…
0
0
0
0
0
onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Sep 15, 2023

1-2> Matching modality to mechanism. The title above is something I've often commented on on Twitter, so it was nice to see. For example, #BMS has seen #GPRC5D as a more appropriate modality for cell therapy than bispecific antibodies, though I don't know the specific reasons.

onco_park's tweet image. 1-2> Matching modality to mechanism. The title above is something I've often commented on on Twitter, so it was nice to see. For example, #BMS has seen #GPRC5D as a more appropriate modality for cell therapy than bispecific antibodies, though I don't know the specific reasons.
0
0
0
2
1K
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Sep 30, 2022

🩸 Le #CAR_T ciblé par #GPRC5D est prometteur dans le #MyélomeMultiple fortement prétraité. 👉 Sur les 17 patients traités, 12 patients ont obtenu une réponse, dont 6 ont obtenu une réponse complète. #MCARH109 #BCMA #CAR_Tcell #Myélome 🩸 cgtlive.com/view/gprc5d-ta…

jyves94's tweet image. 🩸 Le #CAR_T ciblé par #GPRC5D est prometteur dans le #MyélomeMultiple fortement prétraité. 👉 Sur les 17 patients traités, 12 patients ont obtenu une réponse, dont 6 ont obtenu une réponse complète. #MCARH109 #BCMA #CAR_Tcell #Myélome 🩸 cgtlive.com/view/gprc5d-ta…
0
0
0
0
0
BertrandBio's profile picture. Views=mine only, RT-like=/=endorse, no advice. 16y in Tech (chip design) & 10y following bios. Preplanned pause.
Bertrand Delsuc
 @BertrandBio
Dec 12, 2022

Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…

BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
BertrandBio's tweet image. Bristol Myers Squibb $BMY Announces First Disclosures and New Data at #ASH22, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio #GPRC5D CAR-T / Abecma / #BCMA TCE alnuctamab / #cellmods businesswire.com/news/home/2022…
0
0
2
1
0
onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Nov 3, 2023

BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…

onco_park's tweet image. BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…
onco_park's tweet image. BMS-986393 (#GPRC5D CAR-T). We will need to look at the adverse event profile by dose. ash.confex.com/ash/2023/webpr…
0
0
0
0
185
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 10, 2022

🩸 L'essai de la thérapie #CAR_TCell ciblant le #GPRC5D montre son efficacité dans le #MyélomeMultiple résistant R/R, & révèle des #Rémissions chez 70,6 % des patients inscrits. 👉 Le #CAR_T a produit des résultats impressionnants ! #CARTCR #ImmunoTherapy buff.ly/3MdehGe

jyves94's tweet image. 🩸 L'essai de la thérapie #CAR_TCell ciblant le #GPRC5D montre son efficacité dans le #MyélomeMultiple résistant R/R, & révèle des #Rémissions chez 70,6 % des patients inscrits. 👉 Le #CAR_T a produit des résultats impressionnants ! #CARTCR #ImmunoTherapy buff.ly/3MdehGe
0
0
0
0
0
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Jan 31, 2023

⚡️#TheLancet 👉Cellules #CAR_T #GPRC5D (#OriCAR_017) chez des patients atteints d’un #MyélomeMultiple #POLARIS en R/R, 1er essai de #Phase1 chez l’homme 👉La thérapie par #CAR_T ciblant #BCMA a montré une activité dans le traitement du #MyélomeMultiple R/R thelancet.com/journals/lanha…

jyves94's tweet image. ⚡️#TheLancet 👉Cellules #CAR_T #GPRC5D (#OriCAR_017) chez des patients atteints d’un #MyélomeMultiple #POLARIS en R/R, 1er essai de #Phase1 chez l’homme 👉La thérapie par #CAR_T ciblant #BCMA a montré une activité dans le traitement du #MyélomeMultiple R/R thelancet.com/journals/lanha…
0
0
0
0
66
onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Sep 1, 2023

#MultipleMyeloma Studying the mechanisms of resistance to #Talquetamab: Based on a small patient sample, this study showed two mechanisms of resistance induced by the inability of talquetamab to bind to #GPRC5D. While resistance to GPRC5D by 1) genetic mutation is familiar,

onco_park's tweet image. #MultipleMyeloma Studying the mechanisms of resistance to #Talquetamab: Based on a small patient sample, this study showed two mechanisms of resistance induced by the inability of talquetamab to bind to #GPRC5D. While resistance to GPRC5D by 1) genetic mutation is familiar,
1
0
0
0
477
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Feb 5, 2023

🩸 L'essai de #Phase1 #POLARIS ciblées par #GPRC5D a montré un taux de réponse global de 100 % pour #OriCAR_017, une nouvelle thérapie #CAR_Tcell avec une nouvelle cible dans le #MyélomeMultiple R/R. targetedonc.com/view/gprc5d-ta…

jyves94's tweet image. 🩸 L'essai de #Phase1 #POLARIS ciblées par #GPRC5D a montré un taux de réponse global de 100 % pour #OriCAR_017, une nouvelle thérapie #CAR_Tcell avec une nouvelle cible dans le #MyélomeMultiple R/R. targetedonc.com/view/gprc5d-ta…
0
0
0
0
276
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Dec 20, 2022

Johnson & Johnson cherche à obtenir l'approbation de la #FDA pour un médicament contre le #MyélomeMultiple qui pourrait devenir le 1er à cibler une cible appelée #GPRC5D Les données de l'étude soutenant la demande de licence ont été présentées à l'#ASH22 medcitynews.com/2022/12/jj-aim…

jyves94's tweet image. Johnson & Johnson cherche à obtenir l'approbation de la #FDA pour un médicament contre le #MyélomeMultiple qui pourrait devenir le 1er à cibler une cible appelée #GPRC5D Les données de l'étude soutenant la demande de licence ont été présentées à l'#ASH22 medcitynews.com/2022/12/jj-aim…
0
0
0
0
68
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Jul 2, 2022

🩸 Le #Talquetamab est un anticorps bispécifique expérimental, prêt à l'emploi, qui redirige les lymphocytes T ciblant à la fois le #GPRC5D, une nouvelle cible médicamenteuse, sur les cellules de #Myélome_Multiple et le #CD3 sur les #LymphocytesT.

jyves94's tweet image. 🩸 Le #Talquetamab est un anticorps bispécifique expérimental, prêt à l'emploi, qui redirige les lymphocytes T ciblant à la fois le #GPRC5D, une nouvelle cible médicamenteuse, sur les cellules de #Myélome_Multiple et le #CD3 sur les #LymphocytesT.
0
0
0
0
0
Haematologica's profile picture. Haematologica: the journal of the Ferrata Storti Foundation
Haematologica
 @Haematologica
Mar 4, 2024

SpotlightReview: administration, safety, tolerability and toxicities of #Talquetamab a new bispecific antibody targeting #GPRC5D and #CD3 for the treatment of relapsed or #refractoryMultipleMyeloma. haematologica.org/article/view/h…

Haematologica's tweet image. SpotlightReview: administration, safety, tolerability and toxicities of #Talquetamab a new bispecific antibody targeting #GPRC5D and #CD3 for the treatment of relapsed or #refractoryMultipleMyeloma. haematologica.org/article/view/h…
0
10
11
3
2K
jyves94's profile picture. La vie ce n'est pas d'attendre que les orages passent, c'est d'apprendre à danser sous la pluie
Jyves94 🧬
 @jyves94
Oct 8

Thérapie par #CAR_T 🧬 ciblée par #GPRC5D (#CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme. Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20). thelancet.com/journals/lanha…

jyves94's tweet image. Thérapie par #CAR_T 🧬 ciblée par #GPRC5D (#CT071) pour le #MyélomeMultiple 🩸 R/R : 1er essai de phase 1 chez l’homme. Le taux de réponse est de 100 % (IC à 95 % : 83,2-100), avec une réponse complète ou un taux supérieur de 50 % (dix patients sur 20). thelancet.com/journals/lanha…
0
1
1
0
46
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
Jun 26

Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as #GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory #MM. Learn more: hubs.ly/Q03tTTZk0

OncLearnNetwork's tweet image. Syed Maaz Tariq, MD, shares results from a retrospective analysis showing non-BCMA CAR T-Cell therapies, such as #GPRC5D, demonstrate efficacy and safety for patients with relapsed/refractory #MM. Learn more: hubs.ly/Q03tTTZk0
0
0
0
0
55
TribuneK_Hemato's profile picture. Un nouveau fil d'actualité scientifique en #hématologie au travers de nos plateformes numériques. Suivez également Tribunek_Onco @TribuneKa
TribuneK-Hemato
 @TribuneK_Hemato
Apr 19, 2023

Retrouvez dans notre rubrique Myélome, l’analyse commentée rédigée par Sarah CAYLA sur l’article de Chari A, et al. N Engl J Med 2022 ➡️ tribunek-hemato.fr #myélome #Talquetamab #GPRC5D

TribuneK_Hemato's tweet image. Retrouvez dans notre rubrique Myélome, l’analyse commentée rédigée par Sarah CAYLA sur l’article de Chari A, et al. N Engl J Med 2022 ➡️ tribunek-hemato.fr #myélome #Talquetamab #GPRC5D
0
0
0
0
141
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
Mar 27, 2023

Although the #GPRC5D gene is typically expressed in hair follicles, CD138-positive multiple myeloma cells have also been found to express GPRC5D. Learn more about the GPRC5D gene in its #BiologicalPathwayReview! hmpgloballearningnetwork.com/site/onc/biolo…

OncLearnNetwork's tweet image. Although the #GPRC5D gene is typically expressed in hair follicles, CD138-positive multiple myeloma cells have also been found to express GPRC5D. Learn more about the GPRC5D gene in its #BiologicalPathwayReview! hmpgloballearningnetwork.com/site/onc/biolo…
0
0
0
0
98
onco_park's profile picture. Biotech & 💊 innovative drugs. Focused on 🔬 oncology. Expert in 📊 market & industry analysis. #NewDrugs #BioInsights #LetsConnect
Byung-June Park
@onco_park
Oct 12, 2023

1> Relapse and Antigen Loss: Of the patients who responded, six relapsed after 3 to 9 months. These patients showed a decrease or complete loss of #GPRC5D protein expression. Ref: abit.ly/u1vbnc

onco_park's tweet image. 1> Relapse and Antigen Loss: Of the patients who responded, six relapsed after 3 to 9 months. These patients showed a decrease or complete loss of #GPRC5D protein expression. Ref: abit.ly/u1vbnc
1
0
0
0
909
docbraunstein's profile picture. Hematologist/Oncologist and @nyulisom_hemonc Fellowship Program Director @nyulangoneli #hemeonc #multiplemyeloma #myeloma #mmsm #lymphoma. Tweets are my own.
Marc Braunstein, MD, PhD, FACP
 @docbraunstein
Sep 23, 2022

Great work by Sham Mailankody, ⁦@ESmithMDPhD⁩, and team on #GPRC5D #CART in #myeloma #mmsm

docbraunstein's tweet image. Great work by Sham Mailankody, ⁦@ESmithMDPhD⁩, and team on #GPRC5D #CART in #myeloma #mmsm
2
10
46
4
0
_timos_'s profile picture. BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Dr Timos Papagatsias
 @_timos_
Oct 13

LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!

_timos_'s tweet image. LucidQuest Updates > Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025) dlvr.it/TNfK9P #BioPharmaandTechNews #HematologyNews #GPRC5D Comment below!
0
0
0
0
17
OncLearnNetwork's profile picture. Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Oncology Learning Network
 @OncLearnNetwork
May 13

CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0

OncLearnNetwork's tweet image. CAR T-Cell therapy targeting #GPRC5D was found to be safe and effective for the treatment of relapsed/refractory #MM, according to a recent systematic meta-analysis. Learn more: hubs.ly/Q03mdDcN0
0
0
0
0
52

Something went wrong.


Something went wrong.


United States Trends